Objectives: To compare the efficacy of pre-emptive versus empirical antifungal therapy in children with cancer, fever and neutropenia.
Introduction
Invasive fungal disease (IFD) causes significant morbidity and mortality in paediatric cancer patients with high-risk febrile neutropenia (HRFN), along with high utilization of resources for prevention, diagnosis and treatment. [1] [2] [3] [4] Early diagnosis of IFD and prompt implementation of aggressive antifungal treatment have proven to be critical for patient survival. 5, 6 Nevertheless, early identification of the causal pathogen of an IFD continues to be difficult.
The classic approach is currently based on clinical, imaging, microbiological (cultures from sterile sites) and histological studies. Major advances for early diagnosis of IFD have been made by the development of non-culture assays such as detection of galactomannan (GM) antigen, (1-3)-b-D-glucan antigen detection and nucleic acid detection, by PCR techniques. 7, 8 Despite these advances, IFD diagnosis continues to be a challenge 9, 10 and current recommendations propose to initiate empirical antifungal therapy in IFD V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
high-risk paediatric patients with persistent (96 h) fever and neutropenia that are unresponsive to broad-spectrum antibacterial agents. 11 The downside of this approach is the overtreatment of patients meeting the above criteria but who do not have an IFD, leading to an increase in adverse events, prolonged hospitalizations and elevated costs associated with the use of antifungal drugs.
12
A more reasonable approach in cancer subjects would be to consider early identification of patients at high risk of IFD, application of a complete screening diagnosis strategy followed by a rational approach to antifungal therapy based on results of this early and extensive diagnostic workup, adopting a more selective preemptive treatment strategy in patients with persistent fever and neutropenia. 13 Studies aiming to reduce empirical antifungal overtreatment based on pre-emptive strategies have been published on adult patients with cancer and persistent fever and neutropenia. [14] [15] [16] [17] [18] [19] A meta-analysis published in 2015 reviewed nine studies, including randomized controlled trials, cohort studies and feasibility studies, and demonstrated that in adult populations a pre-emptive strategy was associated with significantly lower antifungal exposure (relative risk 0.48; 95% CI 0.27-0.85) without an increase in IFD-related mortality (relative risk 0.82; 95% CI 0.36-1.87) or overall mortality (relative risk 0.95; 95% CI 0.46-1.99). 20 Similar studies in paediatric populations, to our knowledge, have not been performed.
In this study we aim to determine the efficacy of pre-emptive treatment compared with current standard empirical antifungal treatment in children with cancer and HRFN.
Methods

Population
From July 2013 to December 2016, a prospective, randomized, multicentre, government-sponsored study was conducted in five hospitals in Santiago, Chile, that belong to the National Child Programme of Antineoplastic Drugs network. Children and adolescents with cancer, 18 years of age, admitted because of a febrile neutropenic episode were invited to participate and enrolled after parental and child informed consent or assent (when older than 8 years of age). Children with HSCT or under prophylaxis with 
Overall study design
Each child with an episode of febrile neutropenia was classified at admission as having low-risk febrile neutropenia (LRFN) or HRFN based on the following parameters: type of cancer, type and date of last chemotherapy, blood pressure, haematological status [absolute neutrophil count (ANC) and platelet count] and quantitative C-reactive protein (CRP). 21, 22 The microbiological diagnosis protocol included central and peripheral automated blood cultures and other cultures if clinically indicated. After this initial evaluation, all children were treated according to the guidelines for the management of febrile neutropenia in children with cancer. 23, 24 Briefly, all children were hospitalized and those with LRFN were treated with a thirdgeneration cephalosporin (ceftriaxone) whereas children with HRFN were treated with an anti-pseudomonal third-generation cephalosporin (ceftazidime) plus amikacin, with or without an anti-Gram-positive b-lactam or glycopeptide antimicrobial. Children with HRFN episodes who continued with fever and neutropenia at day 4 of antimicrobial treatment were subject to a 1:1 simple randomization by the blinded study coordinator using statistical Santolaya et al.
software (GraphPad Prism, version 6.01; GraphPad, San Diego, CA, USA) into two groups. One group followed current recommendations receiving empirical antifungal treatment starting on day 4 and the second group followed a novel pre-emptive treatment protocol receiving antifungal therapy, at any time of the follow-up, only if persistent fever and ANC 500/mm 3 were accompanied by any of the following findings suggesting IFD: 20 (i) clinical/imaging documented pneumonia or sinusitis (characteristic chest or sinus CT scan); (ii) skin lesions suggesting IFD; (iii) clinical/imaging enterocolitis; (iv) unexplained CNS symptoms; (v) splenic or hepatic characteristic imaging; (vi) single positive GM; or (vii) positive mycological finding.
All children, randomized to empirical or pre-emptive therapy, were evaluated with a standardized clinical, laboratory, imaging and microbiological panel for IFD. The evaluation included ANC, absolute monocyte count (AMC), CRP, repeat blood cultures, serum GM, chest and sinus CT scan, abdominal ultrasound and other imaging studies and diagnostic evaluations according to clinical presentation [fundoscopy, echocardiography, MRI, bronchoalveolar lavage (BAL), skin or other tissue biopsy].
Antifungal agents, in the empirical and pre-emptive groups, included liposomal amphotericin B, echinocandins or voriconazole, according to clinical and laboratory findings. Both groups were monitored until day 30 after enrolment for clinical, laboratory, imaging and microbiological resolution. Two investigators evaluated all cases at day 30, according to the primary and secondary endpoints, blind to information on randomization. Antifungal treatment was stopped or prolonged according to clinical, laboratory, imaging and microbiological findings in each individual case. Children who died were evaluated by a panel of experts including oncologists and infectious diseases specialists from all participating hospitals to determine if the death was or was not related to IFD.
According to Ethics Committee requirements, it was possible to randomize each child in only one episode of febrile neutropenia that met study criteria; for this reason, one randomized episode of HRFN was equivalent to one randomized patient.
Study endpoints
The primary endpoint was overall mortality at day 30 of follow-up. Secondary endpoints included IFD-related mortality, number of days of fever, number of days of hospitalization, number of days of antifungal use, percentage of episodes that developed an IFD (proven, probable or possible), percentage of episodes requiring modification of initial treatment strategy (introduction of antifungal and antifungal modification) and percentage of episodes that needed ICU admission. 
Sample size
The primary endpoint for this non-inferiority study was overall mortality at day 30 of follow-up. Sample size was calculated considering that overall mortality at day 30 of follow-up in children with persistent HRFN is 6%, as previously reported by our group. 26, 27 Considering the same frequency of overall mortality in both groups, a type I error of 0.05 and a potency of 90%, we calculated that 140 episodes of persistent HRFN were required. Based on our previous experience, we have determined our capacity to enrol 300 febrile neutropenic episodes per year for a total of 1000 episodes in 3.5 years.
Statistical analysis
Categorical variables were compared using the v 2 test or Fisher's exact test depending on the number of episodes per comparison group. Continuous variables were compared according to distribution using Student's t-test or the Mann-Whitney test. Overall mortality risk and the risk for secondary endpoints were evaluated for the exposed compared with the non-exposed groups, calculating the relative risk with the respective 95% CI. Statistical analyses were performed using GraphPad Prism version 6.01 and Stata IC version 14.0.
Results
Population characteristics
A total of 1010/1180 febrile neutropenic episodes were evaluated between July 2013 and December 2016 in the five participating hospitals; 170 episodes were excluded: 97 rejected informed consent, 68 did not meet the inclusion criteria and 5 had incomplete data. Seven hundred and forty-one out of 1010 (73%) episodes were classified as HRFN episodes. At day 4 of follow-up, 153/741 (21%) had persistent HRFN and met the criteria for randomization, of which 149/153 (97%) were randomized, 73 into the empirical group and 76 into the pre-emptive group. Four episodes were not randomized owing to prophylactic use of voriconazole or posaconazole (Figure 1) . Table 1 describes the main clinical characteristics of children with episodes of persistent HRFN randomized to empirical or preemptive antifungal therapy. No significant differences were observed in term of age, sex and type of cancer, with mainly haematological malignancy in both groups (85% and 88%, P " 0.56). Nearly 50% of the children had episodes of HRFN without clinical foci at admission; the other 50% of children had respiratory or intestinal foci.
Outcome of children with persistent HRFN by study group Table 2 shows the clinical outcome of 149 randomized children, according to the intervention. Overall mortality at day 30 of followup was 8% (6/73) in the empirical arm and 5% (4/76) in the preemptive arm, with no difference in risks between groups (P " 0.47). In four of the ten children who died the expert panel concluded that mortality was related to an IFD, 2/73 (3%) in the group with empirical therapy and 2/76 (3%) in the group with pre-emptive therapy, with no difference in risk between groups (P " 0.97). The median number of days of antifungal therapy was 11 in the empirical arm and 6 in the pre-emptive arm (P , 0.001), the median number of days of fever was 9 in both groups (P " 0.76), the median number of days of hospitalization was 19 and 17, in the empirical and pre-emptive arms, respectively (P " 0.15), 12% of children developed IFD in each group (P " 0.92) and the need for ICU was 25% in the empirical arm and 20% in the pre-emptive arm (P " 0.47).
After randomization, 32/76 (42%) children in the pre-emptive group received antifungal therapy within the 30 day follow-up period. The median number of days for the initiation of antifungal therapy in this group was 9 (IQR 7-11). The median number of days of neutropenia showed no difference between groups, with 9 days in the empirical arm (IQR 7-13) and 10 in the pre-emptive arm (IQR 7-15), P " 0.31.
Diagnosis and outcome of children with proven or probable IFD by study group
Eighteen children developed a proven or probable IFD during the study, nine in the empirical group and nine in the pre-emptive group. Possible cases were not considered for the analysis. The median age of children with IFD was similar in the two groups (9 and 8 years in the empirical and pre-emptive groups, respectively, P " 0.81). Most of the children were male (78% in each group, P " 1.00) and had a haematological malignancy (89% and 100% in the empirical and pre-emptive groups, respectively, P " 1.00). The outcome of children with proven and probable IFD was similar, irrespective of whether they were randomized into the empirical or pre-emptive group. The percentage of children with proven or probable IFD who died was 22% in each group (P " 1.00); the median number of days of fever was 13 and 17 (P " 0.18), the median number of days of hospitalization was 21 and 26 (P " 0.50) and the median number of days of antifungal use was 21 and 17 in the empirical and pre-emptive groups, respectively (P " 0.35); 33% in each group required antifungal modification (P " 1.00); and 56% and 44% in the empirical and pre-emptive groups, respectively, needed ICU admission (P " 1.00) ( Table 3) .
The demographic, clinical, imaging and microbiological characteristics of the eighteen children with proven and probable IFD are described in Table 4 . The most common species was Candida spp., causing seven cases of candidaemia. We also had seven cases of invasive aspergillosis, one proven and six probable, all with pneumonia (by clinical and imaging findings) and positive GM detection in serum and/or in BAL. Other diagnoses included Fusarium solani Santolaya et al.
infection, Scedosporium apiospermum brain abscess, Sarocladium kiliense fungaemia and mucormycosis.
Discussion
In our study, pre-emptive antifungal therapy was as effective as empirical antifungal therapy in children with cancer and HRFN, with a significant reduction in antifungal use. A reduction of antifungal use, based on stringent diagnostic criteria, could favour the adoption of evidence-based management strategies in this population. This approach requires optimal laboratory support with rapid turnaround response. Introduction of non-culture-based diagnostic techniques into clinical practice could contribute to better management of these patients, favouring the possibility of patient-based individualized therapy. Active monitoring and early diagnostic workup is a necessary step prior to proposing an evidence-based management strategy. [28] [29] [30] Studies comparing empirical versus pre-emptive antifungal therapy in adult populations have evaluated different endpoints: overall mortality, IFD-related mortality, percentage of patients with final diagnosis of IFD, percentage of patients receiving antifungal therapy and number of days of antifungal treatment. 20 Overall mortality was our primary endpoint in accordance with studies in adult populations and because it represents the most relevant outcome in children.
To our knowledge, this is the first prospective, multicentre, randomized study that compares standard versus pre-emptive antifungal therapy in HRFN children with prolonged fever and neutropenia. The comparative analysis between our study and studies in adult populations must be performed cautiously as populations and outcomes are different. 28 The pending question of which is the best approach to antifungal therapy in children with cancer cannot be definitely answered until other groups replicate these findings.
This study had limitations, including the lack of double-blinding, which was decided on because the majority of these children received antifungal therapy through their central venous catheter. We decided not to use the central venous catheter for a possible placebo in order to avoid potentially deleterious manipulation. Another limitation is that we did not evaluate the toxicity of antifungal therapy. Results in adult populations concluded that pre-emptive antifungal therapy has been related to reduction of antifungal drug use and associated toxicity, without increasing mortality. 20 In our experience, 58% of patients of the pre-emptive group did not receive antifungal therapy, with similar clinical outcome to the empirical group, with the aim of reserving antifungal therapy for the subset of patients who have early evidence of IFD by careful clinical, laboratory, imaging and microbiological assessment.
The main findings of our study lead us to propose a step forward in the rational approach to treating children with cancer focusing on one yet-unresolved issue in the management of the patients: adoption of a more selective pre-emptive antifungal treatment strategy in children with prolonged fever and neutropenia.
